

Patent Application Attorney Docket No. PC10886B

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-1450 on this 3rd day of January 2006. By (Signature of person signing Certificate) Vidya Ramsook-Gosine (Typed or printed name of person) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN RE APPLICATION OF: Anton Fliri APPLICATION NO.: 10/629,220 Examiner: Emily Bernhardt Group Art Unit: 1624 FILING DATE: 07/29/2003 **CYCLOPROPANE:** TITLE: ACYLAMINO **DERIVATIVES** Mail Stop: DD

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s).

> 1. US 58721 02/16/99 11/19/98 2. WO 9851671

Romero, Arthur G. Et al: "Synthesis of Metabolically Stable 3. Arylpiperazine 5-HTIA Receptor Agonists" Bioorg. Med. Chem. Lett. (1992), 2(12), 1703-6, XP001056751

Norman M H et al., "Effects of Linking Bridge Modifications on the 4. Antipsychotic Profile of Some Phthalimide and Isoindolinone Derivatives" Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, no. 1, 1996, pages 149-157, XP000982309

ISSN: 0022-2623

Emilien, Gerard et al: "Dopamine D3 agonists" Expert Opinion on 5. Therapeutic Patents (2001), 11(11), 1713-1728, XP001057496

The references listed in the European Search Report issued by the European Patent Office in relation to EP 1 21 247, which corresponds to the subject application are listed individually in form PTO-FB-A280. A copy of said International Search Report is also enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO-FB-A820 form is not intended to represent or imply that these references are prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 3 Jenney 2006

Mary J. Hosley

Attorney for Applicant(s)

Reg. No. 48,324

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212) 733-0460

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known				
Application Number	10/629,220			
Filing Date	07/29/2003			
First Named Inventor	Anton Fliri			
Art Unit	1624			
Examiner Name	Emily Bernhardt			
Attorney Docket Number	PC10886B			

	U.S. PATENT DOCUMENTS						
		Document Number			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
EXAMINER INITIAL*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
		US 5872119	02/16/99				

FOREIGN PATENT DOCUMENTS							
EXAMINER Cite INITIAL No.1		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			T⁵	
		WO 9851671	11/19/98	·			

	 	_
Examiner Signature	DATE CONSIDERED	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) ⁴For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

				Complete if Known		
			IFORMATION	Application Number	10/629,220	
DISCLOSURE STATEMENT BY APPLICANT				Filing Date	07/29/2003	
				First Named Inventor	Anton Fliri	
	(use as many	sheets a	s necessary)			
				Art Unit	1624	
				Examiner Name	Emily Bernhardt	
				Attorney Docket Number	PC10886B	
Shoot	2	of	2	1		

Examiner Initials	Cite	·	T²
	No.1		
		Romero, Arthur G. Et al: "Synthesis of Metabolically Stable Arylpiperazine 5-HTIA Receptor Agonists" Bioorg. Med. Chem. Lett. (1992), 2(12), 1703-6, XP001056751	
		Norman M H et al., "Effects of Linking Bridge Modifications on the Antipsychotic Profile of Some Phthalimide and Isoindolinone Derivatives" Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, no. 1, 1996, pages 149-157, XP000982309 ISSN: 0022-2623	
		Emilien, Gerard et al: "Dopamine D3 agonists" Expert Opinion on Therapeutic Patents (2001), 11(11), 1713-1728, XP001057496	

EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.